Phase 2 Study of Treatment for Hypoparathyroidism, TransCon PTH, Starts to Enroll Adults
A Phase 2 trial evaluating the efficacy and safety of TransCon PTH — designed to restore parathyroid hormone (PTH) levels within 24 hours — in people with hypoparathyroidism is now enrolling adults in North America and Europe. Called PaTH Forward, the study (NCT04009291) is planning to enroll about 40 patients with hypoparathyroidism who…